Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Medicinova Inc (MNOV)

Medicinova Inc (MNOV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy GlobeNewswire - Thu Dec 18, 5:00AM CST

LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.2900 (+0.78%)
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND GlobeNewswire - Mon Dec 8, 5:00AM CST

LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.2900 (+0.78%)
Message from the CEO to MediciNova Shareholders GlobeNewswire - Mon Dec 1, 5:00PM CST

LA JOLLA, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dear Fellow Shareholders, Following the recent publication in the Journal of Atherosclerosis and Thrombosis , I would like to provide additional...

MNOV : 1.2900 (+0.78%)
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor GlobeNewswire - Tue Nov 18, 5:00AM CST

LA JOLLA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.2900 (+0.78%)
MediciNova: Q3 Earnings Snapshot AP - Wed Nov 12, 4:22PM CST

MediciNova: Q3 Earnings Snapshot

MNOV : 1.2900 (+0.78%)
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards GlobeNewswire - Thu Nov 6, 5:00PM CST

LA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.2900 (+0.78%)
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) GlobeNewswire - Tue Nov 4, 6:00AM CST

LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.2900 (+0.78%)
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication GlobeNewswire - Thu Oct 30, 6:00PM CDT

LA JOLLA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.2900 (+0.78%)
MediciNova to Present at the LD Micro Main Event XIX Investor Conference GlobeNewswire - Mon Oct 6, 7:00AM CDT

LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.2900 (+0.78%)
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast) GlobeNewswire - Mon Sep 22, 7:00AM CDT

LA JOLLA, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.2900 (+0.78%)

Barchart Exclusives

Is Ford a Dividend Stock Worth Buying for 2026 After Its 34% Rise This Year? Barchart - Tue Dec 30, 6:30PM CST
While Ford is up 34% for the year and has a healthy dividend yield of 4.5%, the stock's 2026 forecast does not look too bright. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot